Image

Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.

Description

This multicenter prospective patient registry was developed with the aim of documenting how orthopedic surgeons are utilizing the NanoBone products in acute trauma cases along with relevant patient outcomes. These outcomes include radiographic measures such as fracture healing, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on investigator and patient-based outcome assessments.

The primary objective of this study is to document and analyze the use of NanoBone products in acute trauma cases (as a stand-alone bone graft, or in combination with local bone only, no other bone graft substitute or biologic product used) and determine both radiographic success and clinical outcomes. All product related adverse events will be documented, tabulated, and summarized.

Eligibility

Inclusion Criteria:

  1. Subjects at least 18 years old at the time of injury
  2. Acute fractures, resulting from blunt or penetrating trauma
    • In the extremities or pelvis
    • Requiring surgery
    • Treated emergently, delayed or staged up to 4 weeks from the date of injury
    • Where bone grafting is clinically indicated

Exclusion Criteria:

  1. Certain fracture locations (these apply to non-unions as well)
    • Hand - metacarpals, phalanges
    • Forefoot - metatarsals, phalanges
    • Skull
    • Spine
  2. Fractures requiring definitive fracture stabilization beyond the initial 4 weeks from

    the date of injury

  3. Pathologic fractures secondary to malignancy
  4. Subjects unable to follow recommended post-operative plan and complete follow ups
  5. Subjects unable to complete patient reported outcome measures

Study details

Fractures, Bone

NCT06256458

Artoss Inc.

21 February 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.